A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512891-37-00

Enrollment

Registered

2024-11-22

Start date

Unknown

Completion date

2025-11-06

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

Efficacy will be determined by evaluating the number of new and enlarging T2 lesions on MRI scans

Detailed description

The number and severity of adverse events, Proportion of relapse-free patients, Changes in relapse rate (compared with the year before inclusions), Changes from baseline in mean EDDS scores and supplementary ambulatory clinical outcome measures, change from baseline in T1 Gd and T2 lesion load, atrophy, and total brain volume on MRI scans

Interventions

DRUGtolDC

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Secondary

Measure	Time frame
The number and severity of adverse events, Proportion of relapse-free patients, Changes in relapse rate (compared with the year before inclusions), Changes from baseline in mean EDDS scores and supplementary ambulatory clinical outcome measures, change from baseline in T1 Gd and T2 lesion load, atrophy, and total brain volume on MRI scans	—

Primary

Measure	Time frame
Efficacy will be determined by evaluating the number of new and enlarging T2 lesions on MRI scans	—

Countries

Belgium, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026